§
From the * Department of Biophysical Sciences, Department of Physiology, and § Department of Ophthalmology, School of Medicine,
State University of New York, Buffalo, New York 14214
Metabotropic -aminobutyric acid (GABA) receptors were studied in amphibian retinal ganglion
cells using whole cell current and voltage clamp techniques. The aim was to identify the types of receptor present
and their mechanisms of action and modulation. Previous results indicated that ganglion cells possess two ionotropic GABA receptors: GABAAR and GABACR. This study demonstrates that they also possess two types of metabotropic GABAB receptor: one sensitive to baclofen and another to cis-aminocrotonic acid (CACA). The effects of
these selective agonists were blocked by GDP-
-S. Baclofen suppressed an
-conotoxin-GVIA-sensitive barium current, and this action was reversed by prepulse facilitation, indicative of a direct G-protein pathway. The effect of
baclofen was also partially occluded by agents that influence the protein kinase A (PKA) pathway. But the effect of
PKA activation was unaffected by prepulse facilitation, indicating PKA acted through a parallel pathway. Calmodulin antagonists reduced the action of baclofen, whereas inhibitors of calmodulin phosphatase enhanced it. Antagonists of internal calcium release, such as heparin and ruthenium red, did not affect the baclofen response. Thus,
the baclofen-sensitive receptor may respond to influx of calcium. The CACA-sensitive GABA receptor reduced
current through dihydropyridine-sensitive channels. Sodium nitroprusside and 8-bromo-cGMP enhanced the action of CACA, indicating that a nitric oxide system can up-regulate this receptor pathway. CACA-sensitive and baclofen-sensitive GABAB receptors reduced spike activity in ganglion cells. Overall, retinal ganglion cells possess
four types of GABA receptor, two ionotropic and two metabotropic. Each has a unique electrogenic profile, providing a wide range of neural integration at the final stage of retinal information processing.
The retina has emerged as a model system for the study
of -aminobutyric acid (GABA)1 receptors. It possesses
a diversity of GABAA receptors (GABAAR) (Greferath et
al., 1995
), at least two types of GABAB receptor (GABABR)
(Matthews et al., 1994
; Tian and Slaughter, 1994
), and a GABAC receptor (GABACR) (Cutting et al., 1991
).
These receptors produce a variety of electrogenic effects including the ionotropic increase in chloride conductance and the metabotropic modulation of a calcium conductance and activation of a putative potassium conductance. The ability of GABA to produce this
multiplicity of effects permits a precise and varied integration of synaptic information.
While a plethora of GABA receptors have been identified in retina, often they have been discretely localized to small groups of neurons. For example, in white
perch retina the GABACR has been described in a rod-driven horizontal cell (H4) (Qian and Dowling, 1993),
while in catfish retina this receptor was found in cone-driven, but not rod-driven, horizontal cells (Dong et al., 1994
; Takahashi et al., 1994
). The baclofen-sensitive
GABABR has been identified in fish ganglion cells but
was not seen in fish horizontal or bipolar cells (Bindokas and Ishida, 1991
). In one type of goldfish bipolar
cell a cis -aminocrotonic acid (CACA)-sensitive, but not
the baclofen-sensitive, GABA receptor was detected
(Matthews et al., 1994
). This restricted expression fits a
model in which GABARs are precisely localized so that
each receptor subtype is associated with particular neurons. The implication is that there is a functional correlation between receptor properties, such as conductance and kinetics, and the physiology of the neuron. In this context, Pan and Lipton (1995)
reported that
the GABACR found in rat bipolar cells produced a
smaller and slower current than the GABAAR. It is
tempting to conclude that there is a good match between this receptor and the relatively slow and small responses of the rod pathway.
An alternative model of GABA receptor diversity is
that multiple GABARs may be localized in one cell and
thereby expand the inhibitory capability of that neuron. If present, this confluence of GABA receptor subtypes could be particularly important in retinal ganglion cells, the recipients of powerful GABAergic input
from amacrine cells and the final integrators of retinal
information. Therefore, we examined retinal ganglion
cells to determine their complement of GABA receptors. We previously reported that amphibian ganglion
cells possess two types of ionotropic GABA receptor: GABAA and GABAC (Zhang and Slaughter, 1995). We
find that these neurons also contain two types of metabotropic GABA receptor, one sensitive to baclofen
and the other to CACA. Thus, ganglion cells possess every type of GABA receptor currently identified. Through
these different receptors, GABA regulates chloride and potassium conductances and modulates voltage-dependent calcium conductances. This permits a graded level
of inhibition by parallel deployment of different conductance mechanisms. The GABA receptors can be differentially modulated by the internal or external environment of the ganglion cell, indicating that the balance of receptor inhibition can be tuned.
Experiments were performed in aquatic tiger salamander (Ambystoma tigrinum) retinal slice preparation, which has been described in detail previously (Werblin, 1978; Wu, 1987
). In brief,
the animal was decapitated, double pithed, and the eye was enucleated. The cornea, lens, and vitreous were removed, exposing
the retina. The retina was separated from the pigment epithelium and positioned, photoreceptor side down, on filter paper.
The retina and filter paper were sectioned into 200-300-µm
thick slices. These sections were placed on their sides in a perfusion chamber and positioned on the stage of an upright microscope fitted with Hoffman modulation optics. The retinal layers
and individual neurons could be observed while a microelectrode was positioned for whole cell recording. Low resistance
electrodes (<5 M
) were used to form gigaseals. Recordings
were obtained from neurons in the ganglion cell layer, a somatic
layer that Lukasiewicz and Werblin (1988)
found to be almost exclusively populated by ganglion cells. In some cases the neurons
were stained with Lucifer yellow (0.05% added to pipette solution) and retrospectively identified as ganglion cells.
A few experiments were performed on isolated ganglion cells.
A similar dissection procedure and standard dissociation procedures were employed, as detailed previously (Pan and Slaughter,
1995).
Whole cell pipette solution consisted of (in mM): 106 K-gluconate, 5 NaCl, 2 MgCl2, 5 EGTA, and 5 HEPES, buffered to pH 7.4 with KOH. To reduce calcium channel run-down, the pipette solution also contained an "ATP-regenerating cocktail" consisting of 4 mM ATP, 20 mM phosphocreatine, and 50 U/ml creatine phosphokinase. In experiments to study the CACA-sensitive GABA receptor, the ATP-regenerating system was replaced with 4 mM ATP and 0.3 mM GTP. At the recommendation of one reviewer, a few experiments were performed using nystatin perforated patches. In these cases, the same internal solution was used without the ATP-regenerating medium.
Both voltage steps and ramps were used to evoke currents.
Since the barium currents that we measured were sustained and
showed very little inactivation over this time course, we found
that results using the step and ramp were similar. For convenience, ramp data were most often obtained. The figures in this
paper display the original data and are not corrected for electrode tip potential or series resistance. The cells had high input
resistances so leak subtraction was not necessary. The tip potential was measured for each pipette solution (Neher, 1992), and
the correction factor is mentioned in RESULTS, particularly where
reversal potential measurements are presented. The amplifier
did not have series resistance compensation. Except for perforated patch recordings, access resistance was generally between 6 and 15 M
. This resulted in an offset in the peak barium currents. However, since we were monitoring sustained currents and
examining these currents over a wide range of potentials, this offset did not significantly influence our results. In a few cases,
where a large shift occurred, the data were discarded. When both
tip potential and series resistance voltage offsets were subtracted,
the barium current was calculated to peak near +10 mV. This information was not a topic of this paper, so these calculations were
not routinely done for each cell and the raw data is shown without these corrections. Voltage clamp experiments were performed using an Axoclamp 2A amplifier in continuous voltage
clamp mode and PCLAMP software on a Gateway 486 computer
equipped with a Labmaster A/D board. Analysis was performed
employing PCLAMP, EXCEL, and Origin software.
Control amphibian Ringer's solution consisted of (in mM): 111 NaCl, 2.5 KCl, 1.8 CaCl2, 1 MgCl2, 10 dextrose, and HEPES buffered to pH 7.8 and oxygenated. When calcium currents were studied in isolation, 10 mM BaCl2 and 40 mM tetraethyl ammonium chloride (TEA·Cl) replaced equimolar NaCl in the extracellular medium. Tetrodotoxin (1 µM) was used to block sodium currents. Application of 25 µM CdCl2 suppressed most of the inward current under these conditions, indicating that most, if not all, of the observed current arose from calcium channels. Control and drug containing solutions were applied through a gravity fed system to a manifold in connection with the perfusion chamber containing the retinal slice. Valves controlled drug application, and there was a delay of ~10 s due to exchange time of the system. Alternatively, drugs were applied through a puff pipette positioned at the edge of the retina near the cell of interest. In this case, Ringer's solution was still constantly applied to the retinal slice. When antagonists were tested, they were applied first, then after 30-60 s agonist was applied with antagonist. Generally, one cell was recorded in each retinal slice to avoid residual drug effects. Drug effects described in this paper are steady-state values, usually obtained 30-60 s after drug application.
The drug concentrations required to evoke effects in the slice
preparation were often higher than anticipated, indicating that
there was a diffusion or uptake barrier. For example, 100 µM
GABA had only a small effect in the slice preparation, although it
produced a near maximal effect when applied to isolated ganglion cells (Pan and Slaughter, 1995). This was true for glutamate
as well (Shen and Slaughter, unpublished observations). Therefore, there is probably a disparity between the dose applied and
the effective drug concentration at the receptor. This phenomenon has been noted in retinal slice studies from other laboratories. Also, during the course of these studies we noted a decrease
in the response to baclofen and to cis -aminocrotonic acid. Whether this represented a seasonal change or other effect was unclear. A
series of initial experiments were performed using 100 µM baclofen, later 50 µM baclofen was used. In RESULTS, the average effect of 100 µM baclofen is reported to be greater than the effect
of 50 µM, but this is probably due to the time periods when the
studies were completed. Some experiments compare the effects
of second messenger antagonists with the average effect of 100 or
50 µM baclofen. These antagonist experiments were performed
in periods that overlapped the experiments from which the average data were obtained, and therefore represent ganglion cell
populations with appropriate control responses. In CACA experiments, 5 µM doses produced nearly 50% suppression in early experiments (winter), but only about 20% suppression in later experiments (summer). Again, this may have been due to seasonal
changes or other factors. When comparing data between experiments, we only contrasted effects measured at the same time period (usually the same day or week). All statistical data are presented as means ± SEMs.
SR95531, 2-hydroxysaclofen, nifedipine, nimodipine, trifluoperazine, KN-62, forskolin, H-9, Rp-cAMP, microcystin, calmidazolium, ruthenium red, heparin, NG-monomethyl-L-arginine, and sodium nitroprusside were purchased from Research Biochemicals, Inc. (Natick, MA). CACA was obtained from Tocris Cookson (St. Louis, MO). Cyclosporin A was obtained from Calbiochem Corp. (San Diego, CA). CGP35348 and baclofen were gifts from Ciba-Geigy (Basel, Switzerland). All other chemicals were obtained from Sigma Chemical Co. (St. Louis, MO).
GABA-regulated Currents in Ganglion Cells
The effect of GABA was tested on ganglion cells in the
retinal slice preparation by holding neurons at 70 mV
and then stepping them to various potentials between
120 and +60 mV, as illustrated in the left column of
Fig. 1. Under control conditions (Fig. 1 A), ganglion
cells exhibited two prominent currents: a fast inward sodium current (that was truncated in this figure) and
a large outward potassium current. The effects of a localized puff of GABA (Fig. 1 B) and recovery (Fig. 1 C)
are shown, and the I-V relationships under all three
conditions are illustrated (Fig. 1 D). The currents were
measured at a time corresponding to the peak of the
GABA induced current in Fig. 1 B. The difference current (drug minus control), representing the isolated
GABA current, is plotted in Fig. 1 E. This figure shows
that the GABA-induced current is fairly linear between
100 and
20 mV, and reverses near
60 mV. Correcting for the tip potential indicates that this current
reverses at
69 mV, close to the estimated chloride reversal potential (
72 mV). Numerous reports indicate
that a large portion of this chloride current is due to activation of GABAARs (Miller et al., 1981
; Ishida and Cohen, 1988
; Cohen et al., 1989
; Müller et al., 1992
;
Lukasiewicz and Werblin, 1994
). We found that GABA-activated chloride current in salamander ganglion cells
results from activation of both GABAA and GABAC receptors (Zhang and Slaughter, 1995
).
A notch is apparent in the I-V curve (Fig. 1 E) in the region where high voltage-activated (HVA) calcium currents might arise. This suggests that an additional effect of GABA is to suppress a voltage-activated calcium conductance, resulting in a reduction in an outward potassium conductance. The calcium current was blocked to test this hypothesis. When a protocol similar to that in Fig. 1 E was used in the presence of 100 µM external cadmium (this recording is from a different neuron than the one in Fig. 1, A-E), the GABA I-V curve was relatively linear and lacked the notch (Fig. 1 F). The data support the supposition that the notch was due to the GABA-induced reduction of a calcium-activated outward current. Ensuing experiments indicate that GABA does suppress calcium channel currents.
Receptor Modulation of Calcium Currents
In a number of systems, a baclofen-sensitive GABABR
has been associated with the down-regulation of calcium currents. In retina, this has been reported in a
subset of amphibian bipolar cells (Maguire et al., 1989)
and in goldfish ganglion cells (Bindokas and Ishida,
1991
). We therefore examined the effect of baclofen on calcium channel current in amphibian ganglion
cells. The measurement of calcium channel current required a modified Ringer's solution, which contained
10 mM barium, 40 mM TEA-Cl, and was nominally calcium free. Under these conditions we observed an
HVA, relatively sustained inward current that was
blocked by 100 µM external cadmium (data not
shown). In all these experiments, barium was the charge carrier. Since this current was relatively noninactivating, we found that similar data were obtained using either voltage steps or ramps.
Baclofen suppressed a portion of the HVA barium
current in ganglion cells (Fig. 2). The neuron was held
at 70 mV, stepped to
120 mV, and then the voltage
was ramped to +60 mV in 1 s. This paradigm evoked an
inward barium current (Fig. 2 A1) that was suppressed
approximately 30% by 100 µM baclofen (Fig. 2 A2). Adding 2-hydroxysaclofen (1 mM), an antagonist of baclofen-sensitive GABA receptors (Kerr et al., 1988
), restored the inward current close to its control value (Fig.
2 A3). The lower three panels, taken from recordings
of another ganglion cell, show that picrotoxin, an antagonist of both GABAARs and GABACRs, did not block
the effect of baclofen on the HVA barium current. In
experiments on 73 cells, 50 µM baclofen reduced the
HVA current by 29 ± 1% (mean ± SEM), while in another 22 ganglion cells 100 µM baclofen reduced the barium current by 40 ± 3% (see MATERIALS AND METHODS regarding this difference). In the presence of 100 µM picrotoxin, 100 µM baclofen reduced the barium
current by 44 ± 3% (n = 6), indicating that picrotoxin
did not reduce baclofen's action. This pharmacology leads to the conclusion that amphibian ganglion cells
possess a baclofen-sensitive GABABR that can down-regulate HVA calcium currents.
In previous studies (Tian and Slaughter, 1994),
CGP35348 was found to block baclofen but 2-hydroxysaclofen did not. In the present experiments, both were
effective baclofen antagonists. The difference is that in
the prior experiments the concentration of 2-hydroxysaclofen was 100 µM while in the present experiments that concentration was raised to 1 mM.
To determine if ganglion cells possessed another
GABA receptor, we applied GABA in the presence of
antagonists of the GABAAR, GABACR, and the baclofen-sensitive GABABR. Since 2-hydroxysaclofen is a
weak and competitive antagonist of baclofen-sensitive
GABABRs, we sometimes chose to saturate the baclofen-sensitive receptor instead of blocking it. When GABA
was applied in the presence of SR95531, picrotoxin,
and baclofen, it was still able to produce an additional
suppression of the barium current (Fig. 3 A). In nine
cells tested in this manner, GABA reduced the barium
current by 11 ± 2%. Another GABAR has been identified in goldfish retina and shown to down-regulate
HVA calcium channels in bipolar cells (Matthews et al.,
1994). This has been proposed as a novel type of
GABABR. It can be identified pharmacologically by its
sensitivity to low micromolar concentrations of CACA
and its insensitivity to bicuculline, SR95531, picrotoxin,
baclofen, or 2-hydroxysaclofen.
This receptor is also present in amphibian ganglion
cells. A low micromolar concentration of CACA was
able to reduce the HVA barium current in a reversible
manner (Fig. 3 B). CACA produced a 40% decrease in
the barium current in this neuron. We saw no evidence
that low doses of CACA changed the conductance of
the cell (monitored at negative potentials where voltage-dependent channels were not activated), although
at much higher concentrations it can activate the
GABAAR as well as the GABACR in these cells (Zhang
and Slaughter, 1995). The lower set of panels, taken
from another ganglion cell, show that the effect of
CACA persisted when it is applied in the presence of picrotoxin, which blocked the GABAA&CRs, and 2-hydroxysaclofen, which blocked the baclofen-sensitive GABABR.
As noted by Matthews et al. (1994)
, CACA effects were robust when the inside of the cell was dialyzed with
GTP. With 0.3 mM GTP in the pipette, CACA reduced
the barium current by a mean of 46 ± 5% in nine cells.
When GTP was not included in the pipette solution,
CACA produced a smaller reduction in the barium current of 23 ± 2% in 14 cells. This is different than the
action of baclofen, which did not depend on GTP dialysis. Without GTP dialysis the recovery after CACA treatment was poor. All subsequent CACA experiments described in this report were performed using GTP dialysis.
The GABA experiments in Fig. 3 did not include GTP.
Since different internal solutions were used in recording baclofen-sensitive and CACA-sensitive currents, nystatin perforated patch recordings were used to compare the actions of baclofen, CACA, and GABA while limiting the effects of cell dialysis. High concentrations were used to produce maximal responses to each agonist (50 µM CACA, 100 µM baclofen, and 200 µM GABA). The retina slice was pretreated and continuously superfused with picrotoxin (200 µM) to avoid the effects on ionotropic GABA receptors. In five cells, baclofen was found to reduce the barium current by a mean of 28% (from a control value of 1,028 ± 169 pA to 708 ± 109 pA); CACA reduced the current by 9% (to 924 ± 135 pA); GABA reduced the current by 46% (to 534 ± 82 pA). The response to each agonist was statistically significant (P < 0.05, Wilcoxin's signed-ranks test).
The ionotropic GABACR is sometimes referred to as
CACA-sensitive because CACA can be more effective at
activating the GABACR than the GABAAR (Feigenspan
et al., 1993; Qian and Dowling, 1993
; Pan and Lipton,
1995
). We previously reported that high concentrations of CACA were needed to stimulate the GABACR,
and these concentrations also activated the GABAAR
(Zhang and Slaughter, 1995
). This is in contrast to the
receptor identified in Fig. 3, which is sensitive to low
micromolar concentrations of CACA. To avoid confusion with reports describing CACA sensitivity of the
GABACR or GABAAR, we refer to this receptor as the
CACA-sensitive GABABR (GABAB-CACAR).
Baclofen's Action on Different Types of Calcium Channels
Calcium channel blockers were employed to evaluate
the characteristics of the currents regulated by baclofen or CACA. The left side of Fig. 4 shows examples
of ramp-elicited barium currents in the presence of baclofen alone, the blocker alone, and the combination
of baclofen with the channel blocker. 19 ganglion cells
were used to test the effects of two L-type calcium channel blockers: nimodipine and nifedipine. The effect of
50 µM baclofen alone was tested in 14 of the 19 cells
and found to reduce the barium current by 21 ± 2%.
In the 19 cells, 50 µM nifedipine or nimodipine was applied. This is a concentration found to block baclofen's
effect on L-type calcium channels in bipolar cells in the
same preparation (Maguire et al., 1989). These dihydropyridines reduced the barium current by 17 ± 2%.
In the presence of nifedipine or nimodipine, baclofen
reduced the calcium current in these 19 cells by an additional 22 ± 2%. Thus, baclofen produced approximately the same percent suppression of the calcium
current whether the dihydropyridine channel blockers
were present or not. If baclofen had no effect on the
L-type calcium current, then the percentage suppression by baclofen should be greater in the presence of
these blockers. That is, if these two effects were independent they should be additive. On average, the percent suppression by baclofen was slightly greater in the
presence of the blockers, but this was not statistically
significant. Since the blockers reduced the calcium current by 17% on average, an additive effect would only
alter the percent suppression by baclofen from a mean
suppression of 21% to a mean suppression of 25%
(compared to the observed mean suppression of 22%).
Therefore, we can conclude that baclofen does not act
primarily on L-type channels, although we cannot exclude a small modulation of L-type calcium channels.
The N-type channel blocker, -conotoxin-GVIA, had
a much larger effect on both the calcium current and
baclofen's action (Fig. 4, bottom). In eight cells,
-conotoxin reduced the barium current by 57 ± 7%. In the
presence of
-conotoxin, 50 µM baclofen produced only a 14 ± 3% suppression of the remaining reduced
barium current. Of the eight cells used in these experiments, seven had been previously tested with baclofen
alone. Baclofen had produced a mean barium current
suppression of 37 ± 2%. If baclofen acted exclusively on non-N-type calcium channels, it would be expected
to suppress 86% of the remaining calcium current in
the presence of
-conotoxin. If
-conotoxin-GVIA is
acting selectively, this indicates that a large fraction of
the baclofen effect is on the N-type channel.
The CACA-sensitive GABAB Receptors Act on L-type Calcium Channels
In contrast to the effect of the GABAB-BACLOFENR, the
GABAB-CACAR appears to act predominantly at the dihydropyridine-sensitive calcium channel (Fig. 5). The top
row in this figure shows a recording from one ganglion
cell in which 50 µM nimodipine reduced the voltage-activated barium current. In the presence of nimodipine, 5 µM CACA had little additional effect. After
washout and recovery of the barium current, CACA
alone was able to reduce the barium current. The reduction by CACA was similar to that produced by nimodipine. A summary of data is charted in the lower portion of Fig. 5. The CACA alone data in this chart are
drawn from our initial study of nine ganglion cells in
which 5 µM CACA suppressed a mean of 46 ± 5% of
the barium current. In a different set of ten ganglion
cells, 50 µM nimodipine reduced the barium current
by 25 ± 3%. In these ten neurons, after nimodipine reduced the barium current, CACA in the presence of nimodipine produced an additional barium current reduction of 9 ± 3%. All recordings were performed with
0.3 mM GTP in the patch electrode.
GABABR Effects on Ganglion Cell Spike Activity
A simple method of analyzing the influence of metabotropic GABA receptors on ganglion cells is to use current clamp recordings. The protocol for these experiments was to record from neurons in the ganglion cell
layer under whole cell current clamp and evoke spike
activity by applying 300-ms positive current pulses under control conditions and during application of GABA
agonists (see Fig. 7 A). Both baclofen and CACA produced modest reductions in ganglion cell spike activity
(Fig. 6 A). In experiments on 16 cells, baclofen reduced the number of spikes in every case, with a mean
reduction of 28 ± 12% (P < 0.01, Wilcoxin's signed-ranks test). CACA reduced spike number in all twelve
cells tested, with a mean reduction of 22 ± 8% (P < 0.01, Wilcoxin's signed-ranks test). We also noted that
both agonists produced spike broadening of approximately 30%. Calcium-activated potassium channels alter spike frequency (Hille, 1992), which probably explains these GABAB receptor actions. This assumption
is supported by the observation that cadmium, a calcium channel antagonist, produced effects that were
very similar to CACA or baclofen. An example is shown
in Fig. 6 B, which compares the effects of cadmium and
baclofen on responses to current injections in a ganglion cell. Liu and Lasater (1994a)
found that dopamine produced a similar, though more powerful, suppression of spike activity in turtle ganglion cells.
Baclofen and CACA Act through G-protein Pathways
Transmitter-receptor systems that modulate voltage-
activated calcium channels are generally metabotropic
and blocked by agents that interfere with the G-protein
cascade. This was tested using guanosine 5-O-(2-thiodiphosphate) (GDP-
-S), which blocks G-protein-mediated pathways (Fig. 7). The protocol was similar to previous experiments except that 1 mM GDP-
-S was included
in the pipette. A calcium current was periodically evoked,
then baclofen or CACA was applied. The graphs show
the peak currents before, during, and after prolonged drug application. Baclofen and CACA produced only a
slight reduction in the current. Representative currents, measured at the points marked by numbers on
the graphs, are shown. Similar results were obtained in
six other ganglion cells, indicating that both CACA and
baclofen required functional G-protein systems.
Baclofen's Second Messenger Pathway
The effect of baclofen was reversed by prepulse facilitation. These experiments were performed in isolated
cells. The protocol was to activate high voltage-activated calcium channels by depolarizing the cell to +10
mV, from a holding potential of 70 mV. Then the cell
was prepulsed to +100 mV, then again clamped to +10
mV. Fig. 8 shows superimposed currents obtained under control conditions and in the presence of baclofen.
High concentrations of baclofen were required to activate the GABA receptor in the isolated cell preparation. The reason for this is currently being investigated. However, the effects of baclofen in isolated cells were
similar to those found in the slice, both in terms of
pharmacology (2-hydroxysaclofen sensitivity) and electrogenic action. Under control conditions, the barium
current was of similar magnitude before and after the prepulse. But, in the presence of baclofen, the barium
current was much larger after the prepulse (arrows).
The peak of the barium current in baclofen, after the
prepulse, was similar to the magnitude of the barium
current before baclofen application. Prepulse facilitation has been reported for a number of metabotropic
transmitter systems, including the GABABR. It has been
suggested the phenomenon is indicative of a direct
G-protein modulation of the calcium channel (Boland
and Bean, 1993
; Campbell et al., 1995
).
The effect of baclofen was reduced, but not eliminated, by a variety of agents that interfere with the protein kinase A (PKA) pathway. Examples of the effects of
these agents and a summary of the data are shown in
Fig. 9. Except for forskolin, all drugs were dialyzed into
the cell by including them in the pipette solution. Therefore, the effects of baclofen during dialysis of
these drugs were compared to effects of baclofen on a
control population of neurons. The control data used,
presented above, are that 50 µM baclofen reduced the
HVA calcium current by a mean of 29% (n = 73),
whereas 100 µM baclofen reduced this current by 40%
(n = 22). When H-7, a protein kinase inhibitor, was dialyzed into 11 cells, the effect of 100 µM baclofen was
reduced to approximately half the normal magnitude
(19 ± 3%). But Rp-cAMP, a specific blocker of protein
kinase A, had little effect on the response to baclofen. In the presence of Rp-cAMP, 50 µM baclofen suppressed the calcium current by 22 ± 2% (n = 24),
about 75% of control. If the internal levels of cAMP
were increased by dialysis then the effect of 100 µM baclofen was reduced by about 50% (19 ± 2% suppression in six cells). Forskolin was superfused onto the retina, and, therefore, the effect of forskolin on the calcium current could be measured. When ganglion cells
were exposed to forskolin, it produced a 27 ± 3% suppression of the calcium current. And in the presence of forskolin, 50 µM baclofen produced a 15 ± 3% reduction in the calcium current (n = 11). If baclofen was
acting on calcium channels that were not affected by
forskolin, a suppression of 44% by baclofen would be
anticipated. Therefore, the action of baclofen was significantly occluded by forskolin. The results suggest
that activation of the PKA pathway interferes with the
effects of GABAB-BACLOFENR stimulation.
A few antagonists of other second messenger kinase pathways were tested and found not to alter the action of baclofen. These included a protein kinase C inhibitor, staurosporine, and a tyrosine kinase inhibitor, genistein.
The effects of PKA agonists and antagonists suggest a
role for this pathway in mediating the response to baclofen, whereas the prepulse data suggest a direct
G-protein action that is independent of second messengers such as PKA. This discrepancy could be explained if the PKA system autonomously regulated the baclofen-sensitive calcium channel. Prepulse experiments
supported this proposition (Fig. 10). While the effect
of baclofen was reversed by prepulse facilitation (response 2 in Fig. 10), the action of forskolin was unaffected by the prepulse (response 3). In addition, the effect of baclofen and forskolin together (response 4)
was less than the sum of each agent individually. This
indicates that baclofen and forskolin act in parallel to
reduce the calcium channel activation. Forskolin acts
by a mechanism that differs from that produced by
GABAB-BACLOFENR activation, yet occludes the effect of
baclofen.
The action of baclofen was suppressed by calmidazolium, an inhibitor of calcium-calmodulin. In ten ganglion cells, internal dialysis with 100 µM calmidazolium
reduced the effect of baclofen by an average of 72%
(Fig. 11 C). Internal dialysis with 100 µM trifluoperazine, another calcium-calmodulin inhibitor, reduced baclofen's action by 57% (n = 7). A third inhibitor,
W-7 (100 µM added to pipette), suppressed 43% of the
baclofen effect (n = 5).
Calcium-calmodulin can activate protein kinases and phosphatases. We therefore examined the effect of microcystin LR, an inhibitor of protein phosphatases. An example is shown in Fig. 11, where 50 µM baclofen (Fig. 11 A, trace 2) suppressed the control barium current (trace 1) by 14% in this cell. Microcystin alone produced a very small suppression of the barium current in the same cell (Fig. 11 B, trace 1). But 50 µM baclofen in the presence of microcystin (trace 2) reduced the barium current by 29%. In eleven cells tested in this manner, microcystin enhanced the effect of 50 µM baclofen by 161% (from a mean calcium current suppression of 23 ± 3% to a mean of 37 ± 3%). Internal dialysis of cyclosporin A, a calcineurin phosphatase inhibitor, augmented baclofen's mean effect to 152% of control (n = 7). Okadaic acid, another phosphatase inhibitor, produced a similar enhancement. While blockers of calmodulin-dependent phosphatases had a dramatic effect on baclofen's action, KN-62, a very potent blocker of some calcium-calmodulin kinases, had only a slight suppressive effect (data not shown). Internal dialysis with 50-100 µM KN-62 reduced the baclofen effect by 22% (n = 5).
We did not find any evidence that the calcium-calmodulin modulation of the GABABR pathway resulted from calcium release from internal stores. Neither heparin, a blocker of the IP3 pathway, nor ruthenium red, a blocker of the ryanodine receptor, reduced the effect of baclofen (Fig. 11, D and E). Ruthenium red was tested by placing it in the electrode because extracellular application significantly reduced membrane barium currents. In three cells, 50 µM baclofen in the presence of ruthenium red reduced the barium current by 30 ± 5%. Heparin was also included in the patch pipette solution. After heparin dialysis, 50 µM baclofen still reduced the barium current by 33 ± 1% (n = 7). This suppression by 50 µM baclofen, in the presence of ruthenium red or heparin is very similar to the average effect of 50 µM baclofen alone (29 ± 1% suppression).
Modulation of CACA-sensitive GABAB Receptors
As noted, internal levels of GTP regulate the CACA-sensitive GABABR. Associated with this observation,
GABAB-CACAR activation was significantly (P < 0.01) enhanced by sodium nitroprusside or by 8-bromo-cyclic
GMP, as illustrated in Fig. 12. In these experiments, a
voltage ramp was applied every 30 s and the peak inward
barium current was measured. When 50 µM 8-bromo-
cyclic GMP was superfused on the retinal slice (Fig. 12
A), it produced a modest reduction in the barium current. In the presence of 8-bromo-cGMP, 50 µM CACA
produced a large reduction in the HVA barium current. After recovery, CACA alone was applied and
caused a smaller reduction in the barium current. In
ten cells, CACA in the presence of 8-bromo-cGMP reduced the barium current by 38 ± 4%, while CACA
alone suppressed 12 ± 2% of this current. The same
experiment was performed in the presence of 20 µM
H-9, a blocker of guanylate kinase. Under these conditions the effect of CACA was not enhanced by 8-bromo-cGMP (Fig. 12 B). In ten cells, CACA alone suppressed
15 ± 3% of the barium current, but in the presence of
H-9 and 8-bromo-cGMP only 11 ± 3% of the current
was suppressed. As another control, the retina was superfused with membrane impermeant 100 µM cGMP.
It did not enhance the effect of CACA in any of 16 cells
tested. When the retina was superfused with 300 µM sodium nitroprusside, a generator of NO, it also produced a modest suppression of the peak calcium current and it enhanced the effect of CACA (Fig. 12 D). In
seven cells, CACA alone produced a 6 ± 1% calcium
current suppression, while in the presence of sodium
nitroprusside CACA suppressed 21 ± 6% of the calcium current. NG-monomethyl-L-arginine, an inhibitor
of nitric oxide synthase, was tested in four ganglion
cells, but alone it did not suppress the effect of CACA
(data not shown). These results indicate that nitric oxide stimulation of cGMP can up-regulate the CACA-sensitive GABA receptor, but that the NO system is not
endogenously active under the conditions of our experiments.
GABA Receptor Diversity in Ganglion Cells
This study reveals that amphibian ganglion cells contain two distinct metabotropic GABA receptors: GABAB-BACLOFENR and GABAB-CACAR. These neurons also possess
two ionotropic GABA receptors, GABAAR and GABACR,
which regulate chloride conductances (Zhang and
Slaughter, 1995). Although we did not test for all of the
GABARs on each ganglion cell, each receptor subtype
was found on almost all neurons examined, indicating
that most ganglion cells contain all four subtypes. The
GABAAR is a rapid onset, fast desensitizing receptor, while the GABACR has slower activation kinetics but
shows little desensitization (Qian and Dowling, 1993
;
Feigenspan et al., 1993
; Amin and Weiss, 1994
). Therefore, the GABAAR may be more influential in phasic inhibition while the GABACR may produce more tonic
inhibition. A similar separation of function occurs between the two metabotropic GABARs. Both down-regulate calcium currents, but they affect different types of
calcium channel, they act through different second
messenger pathways, and they are differentially regulated. Furthermore, the GABAB-BACLOFENRs also activate
a small potassium conductance (Slaughter and Bai,
1989
; Zhang and Slaughter, personal communication), while the GABAB-CACARs do not. It fits the premise that
the inhibitory GABAergic input to ganglion cells is
eclectic, allowing a spectrum of inhibitory responses to
the same transmitter. A preliminary report of a similar
diversity of GABA receptors in turtle retinal ganglion
cells (Liu and Lasater, 1994b
) suggests this is a general characteristic of these neurons. As discussed below,
each receptor pathway can be differentially modulated,
indicating that the relative weighting of this panoply of
GABA inhibition is transformable.
Modulation of the GABAB-BACLOFENR Transduction Pathway
The action of GDP--S indicates that the GABAB-BACLOFENR
acts through a G-protein pathway (Fig. 7), and prepulse
experiments suggest that a G-protein subunit may directly modulate the calcium channel (Boland and
Bean, 1993
). Forskolin and internal cAMP reduced the
effect of baclofen, but even relatively high doses of
these agents did not eliminate baclofen's effect. Moreover, the effect of baclofen was reversed by prepulse facilitation while forskolin's action was unaltered by this
protocol. Therefore, it is likely that PKA activates a second, parallel pathway that independently down-regulates the same channels affected by baclofen.
Blocking of calcium-calmodulin with calmidazolium, trifluoperazine, or W-7 largely suppressed GABAB-BACLOFENR action. None of these agents alone produced an obvious alteration in the calcium current. Subtle changes would be difficult to detect because all drugs were applied by internal dialysis and therefore were compared statistically to other neurons that served as a control. Calcium-calmodulin stimulates a number of pathways, including specific phosphatases and kinases. KN-62, a potent blocker of some calcium-calmodulin kinases, did not suppress the effect of baclofen. Blockers of calcium-calmodulin dependent phosphatases, such as cyclosporin A and microcystin, enhanced the effect of baclofen. Phosphatase inhibitors did not appear to have a direct effect on the calcium current, indicating that phosphorylation enhanced the GABAB-BACLOFENR pathway.
Thus, calmodulin-dependent phosphatases down-regulated the GABAB-BACLOFENR. But calmodulin antagonists reduced the effect of baclofen, indicating that calmodulin stimulation is required for GABAB-BACLOFENR activity. Therefore, another calmodulin pathway must be involved, possibly a calmodulin-dependent kinase. The ineffectiveness of KN-62 prevents clear identification of a calmodulin kinase, but the action of H-7 (coupled with the ineffectiveness of Rp-cAMP) could be interpreted as a block of a calmodulin-kinase pathway. While the precise calmodulin kinase pathway was not identified, these experiments suggest a regulatory scheme In which calmodulin modulates the activity of the GABA receptor by both up-regulation through kinase activation and down-regulation through phosphatase activation.
A tentative model of GABAB-BACLOFENR transduction
consistent with our data (Fig. 13) proposes that baclofen down-regulates N-type calcium channels through
a direct G-protein pathway. The GABAB-BACLOFENR is biphasically modulated by calmodulin: up-regulation of
the receptor by calmodulin, probably through a kinase,
and down-regulation through a calmodulin-dependent
phosphatase. The balance between these two calmodulin-dependent enzymes would determine the phosphorylation state, and therefore the activity, of this transduction pathway. In addition, a parallel PKA pathway
also down-regulates the same population of calcium
channels.
One ramification of the model is that the calcium-calmodulin system provides a feedback loop between the calcium channel and the GABAB-BACLOFENR. The GABAB-BACLOFENR pathway does not appear to require calcium from internal stores (based on the heparin and ruthenium red data). Therefore, calcium influx through the voltage-sensitive calcium channel may stimulate calmodulin, which up-regulates the GABAB-BACLOFENR. A check on this negative feedback would be the phosphatase system, which turns off the baclofen receptor. This mechanism could help to regulate the internal calcium concentration. The model implies that the calmodulin activation of kinases and phosphatases have different calcium sensitivities or that there is higher gain in the kinase circuit.
Modulation of GABAB-CACAR Action
Considering the variety of GABA receptors in ganglion
cells, changes in the weighting between different receptors can serve to alter the postsynaptic response to the
same presynaptic GABAergic inputs. Second messengers can modulate each GABA receptor. We found that
internal dialysis with ATP or GTP shifted the relative effectiveness of the GABAB-BACLOFENR and GABAB-CACAR,
respectively. Related to this effect, 8-bromo-cGMP or sodium nitroprusside augmented the effects of CACA application. This implies that NO stimulation of guanylate
cyclase can enhance the effectiveness of the GABAB-CACAR-activated second messenger cascade. However, NO antagonists alone did not decrease the effect of CACA, indicating that NO production was normally low under
the conditions of our experiments. Liepe et al. (1994)
found that many cells in the tiger salamander retina have
the ability to synthesis NO. Amacrine, ganglion, and
Müller cells all have this capability and are positioned
to affect the ganglion cell GABAB-CACAR.
Many regulatory mechanisms also produce differential effects on ionotropic GABARs. For example, protein kinase C reduces GABACR and enhances GABAAR
currents (Dong and Werblin, 1994; Feigenspan and
Bormann, 1994
; Wellis and Werblin, 1995
). Similarly,
low micromolar concentrations of zinc can reduce the
GABACR current but enhance the GABAAR current
(Chappell et al., 1995
). Zinc is believed to be synaptically released by photoreceptors (Wu et al., 1993
). Overall, these modulatory mechanisms can be employed to adjust the balance of inhibitory action produced by the four GABA receptor subtypes and suggests that the effects of the ionotropic receptors are
complementary, as are the metabotropic receptors.
In summary, the range of GABA receptors found on ganglion cells coupled with the ability to modulate their effects extends the processing capabilities at this final step in the retinal network. Modulation of inhibition can be a mechanism to shift the balance of weighted inputs or postsynaptic processing in the retina's output neurons.
Original version received 6 December 1996 and accepted version received 15 April 1997.
Address correspondence to Dr. Malcolm Slaughter, SUNY, Department of Biophysics, 120 Cary Hall, Buffalo, NY 14214. Fax: 716-829-2415; E-mail: mslaught{at}ubmed.buffalo.edu
This research was supported by National Eye Institute grant R01-05725.We thank Ciba-Geigy for the generous gifts of baclofen and CGP35348.